2 results match your criteria: "University of Medicine of Algiers Benyoucef Benkhedda[Affiliation]"
Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Arch Cardiovasc Dis
November 2017
Department of cardiology, Mustapha Hospital university, 1, place du 1(er)-Mai, 16001 Algiers, Algeria; Cardiology Oncology Research Collaborative Group (CORCG), University of Medicine of Algiers Benyoucef Benkhedda, Algiers, Algeria.
Background: High P2Y platelet reactivity (PR) level after primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) affects prognosis and may induce the no-reflow phenomenon.
Aim: To investigate the role of PR in the genesis of microvascular obstruction.
Methods: Patients with STEMI undergoing PPCI within 12hours of symptoms onset were included prospectively.
Assessment for Pulmonary Artery Hypertension Using Clinical and Echocardiographic Criteria in Patients With Systemic Sclerosis.
Am J Med Sci
October 2016
Department of Cardiology, service de cardiologie A2, CHU Mustapha Alger, and Cardiology Oncology Research Collaborative Group, University of medicine of Algiers Benyoucef Benkhedda, Algiers, Algeria.
Background: Prognosis of systemic sclerosis (SSc) is affected by pulmonary artery hypertension (PAH).
Methods: Among 202 patients (mean age: 46.1 ± 13.